


ETCTN Trials by Disease/Treatment Area: Lymphoma



NOTE: * No ClinicalTrials.gov webpage is available currently (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide.

ETCTN Lymphoma Trials (Open as of 6/9/2025)

| Protocol Number | Phase | Protocol Title |
|-----------------|-------|--|
| 10299 | I | A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients |
| 10335 | I | A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL) |
| 10499 | Ib/II | Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas |
| 10508 | I/II | A Phase 1 Study of Nivolumab in Combination with ASTX727 in B-cell Lymphoma (NHL or HL) with an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin lymphoma (HL) |
| 10500 | I | Phase 1/Expansion study of tazemetostat plus belinostat for the treatment of relapsed or refractory lymphoma |
| 10590 | II | A Phase 2 Study of Mosunetuzumab or Rituximab in Nodular Lymphocyte-Predominant Hodgkin Lymphoma |
| 10601 | I | A Phase 1 Study of Mosunetuzumab with Polatuzumab Vedotin and Lenalidomide (M+Pola+Len) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) |
| 10637 | II | Phase 2 Trial of Venetoclax in Classic or Variant Hairy Cell Leukemia |
| 10664 | Ib | Phase 1b Study of Combination Tovorafenib and Rituximab Treatment in Relapsed or Refractory Classical Hairy Cell Leukemia and Phase 2 Randomized Study Comparing Tovorafenib and Rituximab with Cladribine and Rituximab for Front-Line Treatment of Classical Hairy Cell Leukemia |
| 10702 | II | A Phase II Study of Glofitamab for Relapsed/Refractory Mantle Cell Lymphoma in Patients Previously Treated with CD19-Directed CAR T-Cell Therapy |
| 10717 | Ib/II | Phase 1b/2 Trial of Pidnarulex in MYC Aberrant Lymphoma |
| 10727 | Ib | Phase 1b study of teclistamab in relapsed/refractory plasmablastic lymphoma |